Tonix Pharmaceuticals Holding Corp.
TNXPTonix Pharmaceuticals (Tonix Pharmaceuticals Holding Corp.) is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.
Drugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
3
Next Catalyst
May 31, 2026
16wMarket Overview
Stock performance and market intelligence
3 upcoming, 1 past
FDA PDUFA Date TNX-1800 (priority)
For COVID-19. BLA filing. Extracted from SEC filing: 8-K
SourceFDA PDUFA Date TNX-102 SL (standard)
For fibromyalgia. NDA filing. Extracted from SEC filing: 8-K
SourceFDA PDUFA Date TNX-102 SL (standard)
For fibromyalgia. NDA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
TNX-102 SL Tablet, 5.6 mg
Fibromyalgia
TNX-102 SL Tablet, 2.8mg
Fibromyalgia
TNX-102 SL Tablet 2.8 mg
Primary Fibromyalgia
TNX-102 SL
Primary Fibromyalgia
TNX-102 SL 5.6 mg
PTSD
TNX-102 SL 2.8mg
Primary Fibromyalgia
TNX-201
Tension-Type Headache
TNX-1900
Chronic Migraine
TNX-601 ER
Depression
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
TNX-102 SL Tablet, 5.6 mg | Phase 3 | Fibromyalgia | - |
TNX-102 SL Tablet, 2.8mg | Phase 3 | Fibromyalgia | - |
TNX-102 SL Tablet 2.8 mg | Phase 3 | Primary Fibromyalgia | - |
TNX-102 SL | Phase 3 | Primary Fibromyalgia | - |
TNX-102 SL 5.6 mg | Phase 3 | PTSD | - |
TNX-102 SL 2.8mg | Phase 3 | Primary Fibromyalgia | - |
TNX-201 | Phase 2 | Tension-Type Headache | - |
TNX-1900 | Phase 2 | Chronic Migraine | - |
TNX-601 ER | Phase 2 | Depression | - |
Regulatory & News
Approvals, filings, and latest developments